Evidence map›Paper›PMID 34523007›Full record

ReviewSkeletal radiology2022

Review of diffusion-weighted imaging and dynamic contrast-enhanced MRI for multiple myeloma and its precursors (monoclonal gammopathy of undetermined significance and smouldering myeloma).

Thomas Van Den Berghe, Koenraad L Verstraete, Frédéric E Lecouvet, Maryse Lejoly, Julie Dutoit

Open access · greenAbstract readReview
PubMed Publisher
In one paragraph

Review in Skeletal radiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Extramedullary Disease-Achilles Heel in Myeloma?American journal of hematology · 2026
    Review
  4. Review
  5. Article
  6. Imaging of Multiple Myeloma: Present and Future.Journal of clinical medicine · 2024
    Review
  7. Article
  8. An MRI-based radiomics nomogram for differentiating spinal metastases from multiple myeloma.Cancer imaging : the official publication of the International Cancer Imaging Society · 2023
    Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Thomas Van Den BergheDepartment of Radiology and Medical Imaging, Ghent University Hospital and Ghent University, Ghent, Belgium. thovdnbe.vandenberghe@ugent.be.ORCID http://orcid.org/0000-0002-0038-8055
Koenraad L VerstraeteDepartment of Radiology and Medical Imaging, Ghent University Hospital and Ghent University, Ghent, Belgium.
Frédéric E LecouvetDepartment of Radiology and Medical Imaging, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (UCLouvain), Brussels, Belgium.
Maryse LejolyDepartment of Radiology and Medical Imaging, Ghent University Hospital and Ghent University, Ghent, Belgium.
Julie DutoitDepartment of Radiology and Medical Imaging, Ghent University Hospital and Ghent University, Ghent, Belgium.
Ghent University Hospital · BEAZ Groeninge · BECliniques Universitaires Saint-Luc · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The last decades, increasing research has been conducted on dynamic contrast-enhanced and diffusion-weighted MRI techniques in multiple myeloma and its precursors. Apart from anatomical sequences which are prone to interpretation errors due to anatomical variants, other pathologies and subjective evaluation of signal intensities, dynamic contrast-enhanced and diffusion-weighted MRI provide additional information on microenvironmental changes in bone marrow and are helpful in the diagnosis, staging and follow-up of plasma cell dyscrasias. Diffusion-weighted imaging provides information on diffusion (restriction) of water molecules in bone marrow and in malignant infiltration. Qualitative evaluation by visually assessing images with different diffusion sensitising gradients and quantitative evaluation of the apparent diffusion coefficient are studied extensively. Dynamic contrast-enhanced imaging provides information on bone marrow vascularisation, perfusion, capillary resistance, vascular permeability and interstitial space, which are systematically altered in different disease stages and can be evaluated in a qualitative and a (semi-)quantitative manner. Both diffusion restriction and abnormal dynamic contrast-enhanced MRI parameters are early biomarkers of malignancy or disease progression in focal lesions or in regions with diffuse abnormal signal intensities. The added value for both techniques lies in better detection and/or characterisation of abnormal bone marrow otherwise missed or misdiagnosed on anatomical MRI sequences. Increased detection rates of focal lesions or diffuse bone marrow infiltration upstage patients to higher disease stages, provide earlier access to therapy and slower disease progression and allow closer monitoring of high-risk patients. Despite promising results, variations in imaging protocols, scanner types and post-processing methods are large, thus hampering universal applicability and reproducibility of quantitative imaging parameters. The myeloma response assessment and diagnosis system and the international myeloma working group provide a systematic multicentre approach on imaging and propose which parameters to use in multiple myeloma and its precursors in an attempt to overcome the pitfalls of dynamic contrast-enhanced and diffusion-weighted imaging.Single sentence summary statementDiffusion-weighted imaging and dynamic contrast-enhanced MRI provide important additional information to standard anatomical MRI techniques for diagnosis, staging and follow-up of patients with plasma cell dyscrasias, although some precautions should be taken on standardisation of imaging protocols to improve reproducibility and application in multiple centres.

Indexed as

Monoclonal Gammopathy of Undetermined SignificanceMultiple MyelomaParaproteinemiasContrast MediaDiffusion Magnetic Resonance ImagingHumansMagnetic Resonance ImagingReproducibility of ResultsContrast MediaDiagnosisDiffusion-weighted imagingDynamic contrast–enhanced magnetic resonance imagingFollow-upMagnetic resonance imagingMonoclonal gammopathy of undetermined significanceMultiple myelomaSmouldering myelomaStaging

Identifiers

PMID34523007
OpenAlexW3200158760

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.